BiondVax Pharmaceuticals Ltd. (BVXV): Price and Financial Metrics


BiondVax Pharmaceuticals Ltd. (BVXV): $3.12

0.04 (+1.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BVXV Stock Price Chart Interactive Chart >

Price chart for BVXV

BVXV Price/Volume Stats

Current price $3.12 52-week high $62.00
Prev. close $3.08 52-week low $2.35
Day low $3.00 Volume 54,200
Day high $3.14 Avg. volume 611,372
50-day MA $3.07 Dividend yield N/A
200-day MA $10.06 Market Cap 35.42M

BiondVax Pharmaceuticals Ltd. (BVXV) Company Bio


Biondvax Pharmaceuticals Limited is a pharmaceutical company that develops intra-nasal flu vaccines.


BVXV Latest News Stream


Event/Time News Detail
Loading, please wait...

BVXV Latest Social Stream


Loading social stream, please wait...

View Full BVXV Social Stream

Latest BVXV News From Around the Web

Below are the latest news stories about BiondVax Pharmaceuticals Ltd that investors may wish to consider to help them evaluate BVXV as an investment opportunity.

BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

JERUSALEM , May 13, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV ), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its fourth quarter and full year financial results for the year ended December 31, 2020 and provided a business update. Fourth Quarter 2020 Financial Summary Results are in New Israel Shekels (NIS) and convenience translation to US$ is provided using the exchange rate of 3.215 (NIS/US$), the rate as of the close of business on December 31, 2020 . Total operating expenses for the quarter were NIS 12.3 million ( $3.2 million ) compared with NIS 45.7 million for the fourth quarter of 2019. R&D expenses for ...

Benzinga | May 13, 2021

BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering

JERUSALEM , Feb. 10, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV ), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced that the underwriter of its recent follow-on underwritten offering fully exercised its over-allotment option to purchase 365,217 of BiondVax's American Depositary Shares ("ADS"). The option was granted in connection with the follow-on offering of 2,434,783 ADSs at a public offering price of $4.95 per ADS which closed on February 2, 2020 . The exercise of the over-allotment option brings the total gross proceeds of the offering to approximately $13.8 million . Aegis Capital Corp. acted as sole bookrunnin...

Benzinga | February 10, 2021

BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering

JERUSALEM, Israel, Feb. 2, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today…

PR Newswire | February 2, 2021

BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares

JERUSALEM, Jan. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced…

PR Newswire | January 29, 2021

BiondVax Announces Appointment of Amir Reichman as New CEO

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment of infectious diseases, today announced the appointment of Amir Reichman as its new CEO. Mr. Reichman and Ron Babecoff, BiondVax's founder and current CEO, will share duties during a transition period while Mr. Reichman completes his work obligations at GlaxoSmithKline (GSK), a global pharmaceutical company. Effective March 2, 2021, Mr. Reichman will assume the CEO position full time and Mr. Babecoff will continue as Senior Advisor to the Company.

Yahoo | January 21, 2021

Read More 'BVXV' Stories Here

BVXV Price Returns

1-mo 8.33%
3-mo -23.53%
6-mo -2.50%
1-year -86.95%
3-year -52.94%
5-year -20.00%
YTD 11.03%
2020 -69.75%
2019 94.76%
2018 -11.01%
2017 60.00%
2016 -15.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8612 seconds.